Literature DB >> 11761428

Molecular pathology of pituitary adenomas.

R V Lloyd1.   

Abstract

A great deal of knowledge about anterior pituitary development, the pathogenesis of pituitary tumor and pituitary tumor progression has accumulated during the past decade. The role of multiple genes and gene products in pituitary development and the relationship of these genes to postnatal pituitary function and pituitary tumor development are being actively explored. Recent studies indicate that genes important in pituitary development do not contribute to pituitary tumorigenesis. However, mutations and other genetic alterations in these genes often lead to pituitary hypofunction. Many oncogenes and tumor suppressor genes that contribute to pituitary tumorigenesis have been described. There is a growing body of evidence showing that cellular and molecular changes in cyclins and cyclin-dependent kinase inhibitors contribute to pituitary tumorigenesis. Finally, recent comparative genomic hybridization studies show that many more genes that are important in pituitary tumorigenesis and tumor progression have yet to be discovered.

Entities:  

Mesh:

Year:  2001        PMID: 11761428     DOI: 10.1023/a:1012940929072

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  69 in total

1.  p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions.

Authors:  K Thapar; B W Scheithauer; K Kovacs; P J Pernicone; E R Laws
Journal:  Neurosurgery       Date:  1996-04       Impact factor: 4.654

2.  Frequent loss of the P16INK4a gene product in human pituitary tumors.

Authors:  M Woloschak; A Yu; J Xiao; K D Post
Journal:  Cancer Res       Date:  1996-06-01       Impact factor: 12.701

3.  Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27.

Authors:  J Vlach; S Hennecke; B Amati
Journal:  EMBO J       Date:  1997-09-01       Impact factor: 11.598

4.  Frequent inactivation of the p16 gene in human pituitary tumors by gene methylation.

Authors:  M Woloschak; A Yu; K D Post
Journal:  Mol Carcinog       Date:  1997-08       Impact factor: 4.784

5.  Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1.

Authors:  K Tomoda; Y Kubota; J Kato
Journal:  Nature       Date:  1999-03-11       Impact factor: 49.962

6.  Characterization of Prophet of Pit-1 gene expression in normal pituitary and pituitary adenomas in humans.

Authors:  Y Nakamura; T Usui; H Mizuta; H Murabe; S Muro; M Suda; K Tanaka; I Tanaka; A Shimatsu; K Nakao
Journal:  J Clin Endocrinol Metab       Date:  1999-04       Impact factor: 5.958

Review 7.  Molecular pathogenesis of pituitary tumors.

Authors:  W E Farrell; R N Clayton
Journal:  Front Neuroendocrinol       Date:  2000-07       Impact factor: 8.606

8.  Analysis of cyclin D1 (CCND1) allelic imbalance and overexpression in sporadic human pituitary tumors.

Authors:  N A Hibberts; D J Simpson; J E Bicknell; J C Broome; P R Hoban; R N Clayton; W E Farrell
Journal:  Clin Cancer Res       Date:  1999-08       Impact factor: 12.531

9.  Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors.

Authors:  K Nakayama; N Ishida; M Shirane; A Inomata; T Inoue; N Shishido; I Horii; D Y Loh; K Nakayama
Journal:  Cell       Date:  1996-05-31       Impact factor: 41.582

10.  Ras mutations in human pituitary tumors.

Authors:  H J Karga; J M Alexander; E T Hedley-Whyte; A Klibanski; J L Jameson
Journal:  J Clin Endocrinol Metab       Date:  1992-04       Impact factor: 5.958

View more
  8 in total

1.  Patterns of gene expression in pituitary carcinomas and adenomas analyzed by high-density oligonucleotide arrays, reverse transcriptase-quantitative PCR, and protein expression.

Authors:  Katharina H Ruebel; Alexey A Leontovich; Long Jin; Gail A Stilling; Heyu Zhang; Xiang Qian; Nobuki Nakamura; Bernd W Scheithauer; Kalman Kovacs; Ricardo V Lloyd
Journal:  Endocrine       Date:  2006-06       Impact factor: 3.633

2.  Inactivation of the p16 gene in human pituitary nonfunctioning tumors by hypermethylation is more common in null cell adenomas.

Authors:  K H Ruebel; L Jin; S Zhang; B W Scheithauer; R V Lloyd
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

Review 3.  DNA microarrays: recent developments and applications to the study of pituitary tissues.

Authors:  Xiang Qian; Bernd W Scheithauer; Kalman Kovacs; Ricardo V Lloyd
Journal:  Endocrine       Date:  2005-10       Impact factor: 3.633

4.  Brain tumor senescence might be mediated by downregulation of S-phase kinase-associated protein 2 via butylidenephthalide leading to decreased cell viability.

Authors:  Mao-Hsuan Huang; Shinn-Zong Lin; Po-Cheng Lin; Tzyy-Wen Chiou; Yeu-Wei Harn; Li-Ing Ho; Tzu-Min Chan; Chih-Wei Chou; Chang-Han Chuang; Hong-Lin Su; Horng-Jyh Harn
Journal:  Tumour Biol       Date:  2014-01-26

Review 5.  Best Practice No 172: pituitary gland pathology.

Authors:  J W Ironside
Journal:  J Clin Pathol       Date:  2003-08       Impact factor: 3.411

Review 6.  Prognostic indicators in pituitary tumors.

Authors:  Agustinus Suhardja; Kalman Kovacs; Oded Greenberg; Bernd W Scheithauer; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2005       Impact factor: 4.056

7.  Promoter hypermethylation profile of cell cycle regulator genes in pituitary adenomas.

Authors:  Atsuo Yoshino; Yoichi Katayama; Akiyoshi Ogino; Takao Watanabe; Kazunari Yachi; Takashi Ohta; Chiaki Komine; Takakazu Yokoyama; Takao Fukushima
Journal:  J Neurooncol       Date:  2007-01-11       Impact factor: 4.506

8.  Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas.

Authors:  Hua Gao; Fei Wang; Xiaolei Lan; Chuzhong Li; Jie Feng; Jiwei Bai; Lei Cao; Songbai Gui; Lichuan Hong; Yazhuo Zhang
Journal:  BMC Cancer       Date:  2015-04-12       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.